Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study

(2019) Brittany Knick Ragon et al.   Clinical Lymphoma Myeloma & Leukemia

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

(2018) Anthony W. Tolcher et al.   MOLECULAR CANCER THERAPEUTICS

MEK inhibitors for the treatment of NRAS mutant melanoma

(2018) Saro Sarkisian et al.   Drug Design Development and Therapy

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

(2018) Eytan M. Stein et al.   BLOOD

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

MiR-21: an environmental driver of malignant melanoma?

(2015) Bodo C Melnik   Journal of Translational Medicine

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

(2015) E. Jokinen et al.   Therapeutic Advances in Medical Oncology

The developing story of Sprouty and cancer

(2014) Samar Masoumi-Moghaddam et al.   CANCER AND METASTASIS REVIEWS

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia

(2014) E Pasmant et al.   ONCOGENE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Antagonistic Feedback Loops Involving Rau and Sprouty in the Drosophila Eye Control Neuronal and Glial Differentiation

(2013) F. Sieglitz et al.   Science Signaling

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group

(2012) Hirozumi Sano et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH

SPRED1 disorder and predisposition to leukemia in children

(2009) E. Pasmant et al.   BLOOD

Sprouty proteins, masterminds of receptor tyrosine kinase signaling

(2008) Miguel A. Cabrita et al.   ANGIOGENESIS

FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging

(2008) K. Miyamoto et al.   BLOOD

Cooperating gene mutations in acute myeloid leukemia: a review of the literature

(2008) A Renneville et al.   LEUKEMIA

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

(2008) Jer-Yen Yang et al.   NATURE CELL BIOLOGY